All In Biotech

Free tool

FAERS Monitor: Rextovy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208969 or its brand name (Rextovy, Naloxone Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

933

Serious

752

81% of reports

Hospitalization

409

Death reported

140

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective97
  • toxicity to various agents90
  • vomiting58
  • fatigue49
  • off label use49
  • overdose48
  • drug withdrawal syndrome46
  • nausea46
  • diarrhoea40
  • pain40
  • febrile neutropenia32
  • fall31
  • unresponsive to stimuli31
  • drug abuse30
  • drug dependence30

Reports by year received

View as table
YearReports
20041
20051
20072
20083
200910
20108
20113
20129
20139
201410
201515
201626
201735
201859
201950
2020128
202185
2022106
202394
2024117
2025103
202659

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,226 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
unresponsive to stimuliSignal3127.119.2754
toxicity to various agentsSignal9012.09.9907
drug withdrawal syndromeSignal4611.88.9447
febrile neutropeniaSignal3210.97.7278
drug abuseSignal308.15.7181
overdoseSignal485.03.8152
drug dependenceSignal304.23.071
vomitingSignal582.82.266
fallSignal312.11.517
drug ineffective971.71.426
pain401.51.16
fatigue491.41.16
diarrhoea401.41.04
nausea461.31.03
off label use491.31.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.